PPARG and diabetic kidney disease: PPARγ agonists have a beneficial impact on several kidney illnesses, such as diabetic nephropathy (DN), polycystic kidney disorders, IgA nephropathy, chemotherapy-associated kidney damage, ischemic renal injury, and age-related kidney diseases.